Wednesday, August 5, 2015
Research and Markets: PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023 for the $8.2 Billion Market
… in
the treatment of hormone-sensitive prostate cancer.
Furthermore, Raksha Mudbhary, Ph.D … for
the treatment of castration-resistant prostate cancer (CRPC).
However, the analyst notes … CRPC, non-metastatic CRPC and
hormone-sensitive prostate cancer.
Mudbhary explains: Xtandi's …
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment